Structure-Guided Design, Synthesis, and Evaluation of Novel 6-Methoxyquinoline-4-carboxamide Derivatives as First-in-Class Nano-Molar B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma
Authors:
- 11 September 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Abstract
Beta-1,3-glucuronosyltransferase (B3GAT3) is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis, serving as a desirable anti-HCC target. Based on our micromolar lead TMLB-C16 (IC50 = 6.22−6.53 μM, KD = 3.96 μM), 60 novel derivatives were designed via systematic structure−activity relationship optimization. The optimized candidate TMLB-G9 is the first nanomolar B3GAT3 inhibitor bearing a 6-methoxyquinoline-4-carboxamide scaffold. It exhibits stronger B3GAT3 binding affinity (KD = 0.72 μM) than both TMLB-C16 and natural substrate UDP-GlcUA (KD = 1.32 μM). TMLB-G9 exhibits potent antiproliferative activity against Huh7 and Hep3B cells (IC50 = 0.31−0.36 μM) and broad-spectrum antitumor efficacy. It suppresses HCC colony formation, migration, and invasion, while inducing G0/G1 arrest and apoptosis. With good in vivo tolerance and safety, TMLB-G9 exhibited superior anti-HCC activity to TMLB-C16 in two HCC xenograft models. In conclusion, TMLB-G9 is a promising B3GAT3 inhibitor worthy of further development for HCC therapy.Keywords
Funding Information
- State Key Laboratory of Natural Medicines (SKLNMZZ202309)
- China Pharmaceutical University (2632023GR25)
- Natural Science Foundation of Jiangsu Province (7032300014)
- Natural Science Foundation of Jiangsu Province (BK20231015)
- Joint Project of Health Science and Technology Innovation of Hainan Province (WSJK2025ZD211)
- Anti-tumor New Drug Rapid Translation Public Service Platform of Jiangsu Province (BM2023002)
- Jiangsu Provincial Outstanding Postdoctoral Program (1412300102)
- National Natural Science Foundation of China (NSFC) (82002971)
- National Natural Science Foundation of China (NSFC) (82273972)
- National Natural Science Foundation of China (NSFC) (82330119)
- National Natural Science Foundation of China (NSFC) (82504583)
This publication has 45 references indexed in Scilit:
- Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunitiesHepatology International, 2025
- Divergent trends in the burden of esophageal, gastric, and liver cancers in ChinaJournal of the National Cancer Center, 2025
- Recent Advances in Enzymes and Chemoenzymatic Synthesis of Tetrasaccharide Linkage Region of ProteoglycansChemBioChem, 2025
- The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwideInternational Journal of Cancer, 2024
- Cancer incidence and mortality in China, 2022Journal of the National Cancer Center, 2024
- Advances in the early diagnosis of hepatocellular carcinomaGenes & Diseases, 2020
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamineJournal of Cancer Research and Clinical Oncology, 2017
- Skeletal dysplasia, global developmental delay, and multiple congenital anomalies in a 5‐year‐old boy—Report of the second family with B3GAT3 mutation and expansion of the phenotypeAmerican Journal of Medical Genetics Part A, 2014
- Molecular Cloning and Expression of a Second Glucuronyltransferase Involved in the Biosynthesis of the HNK-1 Carbohydrate EpitopeBiochemical and Biophysical Research Communications, 1999